ImmunityBio resubmits cancer treatment application to FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for subdued open on final trading day of strong quarter
- Strong dollar pushes yen to 40-year low as traders test Japanese authorities
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Logitech dips as BofA downgrades stock on demand outlook concerns
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
March 9, 2026 7:30 AM EDTFollowing multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary diseaseThe FDA reviewed the additional data provided by ImmunityBio in February 2026, and based on the Agency's feedback, the Company resubmitted the sBLAThe FDA has acknowledged receipt of the resubmitted filingThe sBLA aims to address the unmet need for patients with papillary-only NMIBC, supported by what is believed to be the longest... More
